Levepsy RTU 500 Infusion contains Levetiracetam 500 mg, an antiepileptic agent indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam’s mechanism of action is believed to involve modulation of synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby inhibiting seizure propagation. This ready-to-use intravenous infusion formulation allows for rapid administration in clinical settings, particularly when oral administration is not feasible. Levepsy RTU 500 Infusion is typically employed as adjunctive therapy in adults and pediatric patients aged 4 years and above. The infusion should be administered over 15 minutes, with dosing individualized based on renal function and clinical response. Common adverse effects include somnolence, dizziness, headache, and fatigue, with serious neuropsychiatric events being rare but warranting monitoring. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Levepsy RTU 500 Infusion offers a convenient and effective option for seizure control, facilitating prompt therapeutic intervention in acute or perioperative settings. Healthcare professionals should adhere to recommended dosing guidelines and monitor patients for efficacy and tolerability during treatment.